We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

236 hedge funds and large institutions have $3.87B invested in Ultragenyx Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 94 increasing their positions, 75 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 23

54% more capital invested

Capital invested by funds: $2.52B → $3.87B (+$1.36B)

25% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 75

8% more funds holding

Funds holding: 219 → 236 (+17)

0.1% less ownership

Funds ownership: 98.74% → 98.64% (-0.1%)

1% less call options, than puts

Call options by funds: $23.1M | Put options by funds: $23.4M

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

Holders
236
Holders Change
+17
Holders Change %
+7.76%
% of All Funds
3.44%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
44
Increased
94
Reduced
75
Closed
23
Calls
$23.1M
Puts
$23.4M
Net Calls
-$285K
Net Calls Change
-$1.62M

Top Buyers

1
Sands Capital Management
Sands Capital Management
Virginia
+$59.7M
2
RI
RTW Investments
New York
+$57.5M
3
SCM
Suvretta Capital Management
New York
+$56.1M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$55.8M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$36.2M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$44.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$30.3M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$23.8M
4
FLAM
First Light Asset Management
Minnesota
-$14.7M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$9.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
151
Ameriprise
Minnesota
$530K -$171K -4,417 -29%
NIM
152
NEOS Investment Management
Connecticut
$516K +$419K +10,797 New
BA
153
Bridgewater Associates
Connecticut
$509K -$29.2K -754 -7%
Victory Capital Management
154
Victory Capital Management
Texas
$505K +$126K +3,259 +45%
X
155
Xponance
Pennsylvania
$486K +$25.1K +648 +7%
GCM
156
Ghisallo Capital Management
Massachusetts
$478K +$388K +10,000 New
CUAMC
157
China Universal Asset Management Company
China
$454K +$297K +7,670 +419%
SG Americas Securities
158
SG Americas Securities
New York
$440K -$115K -2,957 -24%
C
159
Certuity
Florida
$437K +$355K +9,145 New
Walleye Trading
160
Walleye Trading
New York
$436K -$215K -5,535 -38%
EGM
161
Engineers Gate Manager
New York
$428K -$334K -8,604 -49%
Public Employees Retirement Association of Colorado
162
Public Employees Retirement Association of Colorado
Colorado
$428K – – –
P
163
Pitcairn
Pennsylvania
$413K +$335K +8,636 New
WC
164
Woodstock Corp
Massachusetts
$385K +$312K +8,060 New
GAM
165
Gotham Asset Management
New York
$358K +$290K +7,478 New
XT
166
XTX Topco
Cayman Islands
$354K -$218K -5,613 -43%
LPL Financial
167
LPL Financial
California
$345K -$6.94K -179 -2%
VEA
168
Virtus ETF Advisers
New York
$340K +$40K +1,033 +17%
Verition Fund Management
169
Verition Fund Management
Connecticut
$338K +$274K +7,070 New
US Bancorp
170
US Bancorp
Minnesota
$323K +$8.8K +227 +3%
M&T Bank
171
M&T Bank
New York
$310K +$251K +6,486 New
Mitsubishi UFJ Asset Management
172
Mitsubishi UFJ Asset Management
Japan
$303K +$29.3K +757 +14%
OAM
173
Oppenheimer Asset Management
New York
$301K -$31.9K -823 -12%
Group One Trading
174
Group One Trading
Illinois
$301K +$22.9K +591 +10%
Wealth Enhancement Advisory Services
175
Wealth Enhancement Advisory Services
Minnesota
$295K +$239K +6,176 New
5 6
7
8 9

RARE Hedge Fund Activity: Q4 2023 in Review

236 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2023, worth a combined $3.87B — up 54% from $2.52B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new RARE positions and 23 closed out — a net gain of 21 holders — while 94 added to existing stakes and 75 trimmed.

The largest buyer was Sands Capital Management, adding an estimated $59.7M. The largest seller was Avoro Capital Advisors, cutting an estimated $44.6M.

  • 236 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2023, up from 219 in Q3 2023.
  • Funds reported $3.87B of Ultragenyx Pharmaceutical stock for Q4 2023, up 54% quarter-over-quarter.
  • 44 funds opened new Ultragenyx Pharmaceutical positions in Q4 2023 and 23 closed out, a net change of +21 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q4 2023 was Sands Capital Management, an estimated $59.7M added.
  • The largest Ultragenyx Pharmaceutical seller in Q4 2023 was Avoro Capital Advisors, an estimated $44.6M sold.

Based on aggregated 13F filings for Q4 2023.